CEFTAZIDIME (ceftazidime) by Pfizer is mechanism of action ceftazidime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Approved for including pneumonia, caused by pseudomonas aeruginosa, other pseudomonas spp. First approved in 1985.
Drug data last refreshed 19h ago
Mechanism of Action Ceftazidime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftazidime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.
Worked on CEFTAZIDIME at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
Real-World Study of Ceftazidime Avibactam in China
Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)
Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo